United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension …
Over the last 12 months, insiders at United Therapeutics Corporation have bought $0 and sold $293.09M worth of United Therapeutics Corporation stock.
On average, over the past 5 years, insiders at United Therapeutics Corporation have bought $0 and sold $146.34M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4 shares for transaction amount of $331 was made by PATUSKY CHRISTOPHER (director) on 2019‑06‑10.
2024-11-18 | Sale | PRESIDENT AND COO | 10,000 0.0224% | $359.21 | $3.59M | +1.21% | ||
2024-11-11 | Sale | director | 1,750 0.004% | $412.48 | $721,840 | -4.51% | ||
2024-11-11 | Sale | PRESIDENT AND COO | 15,000 0.034% | $407.32 | $6.11M | -4.51% | ||
2024-11-08 | Sale | director | 224 0.0005% | $412.28 | $92,350 | -2.33% | ||
2024-11-07 | Sale | PRESIDENT AND COO | 15,000 0.0334% | $401.44 | $6.02M | -0.53% | ||
2024-11-06 | Sale | PRESIDENT AND COO | 10,000 0.0222% | $394.96 | $3.95M | +0.74% | ||
2024-11-05 | Sale | director | 10,000 0.0228% | $381.70 | $3.82M | 0.00% | ||
2024-11-04 | Sale | CFO AND TREASURER | 4,511 0.0101% | $374.02 | $1.69M | +6.28% | ||
2024-11-01 | Sale | director | 510 0.0012% | $376.63 | $192,080 | +7.06% | ||
2024-11-01 | Sale | PRESIDENT AND COO | 14,700 0.033% | $374.46 | $5.5M | +7.06% | ||
2024-10-28 | Sale | CFO AND TREASURER | 4,533 0.0096% | $350.00 | $1.59M | +0.80% | ||
2024-10-21 | Sale | CFO AND TREASURER | 4,515 0.01% | $366.99 | $1.66M | +1.67% | ||
2024-10-14 | Sale | CFO AND TREASURER | 4,525 0.0101% | $355.88 | $1.61M | +4.56% | ||
2024-10-07 | Sale | CFO AND TREASURER | 4,527 0.0101% | $355.54 | $1.61M | +5.75% | ||
2024-09-30 | Sale | CFO AND TREASURER | 4,525 0.0102% | $358.62 | $1.62M | +1.52% | ||
2024-09-23 | Sale | CFO AND TREASURER | 4,529 0.0101% | $354.04 | $1.6M | +1.89% | ||
2024-09-16 | Sale | CFO AND TREASURER | 4,543 0.01% | $339.12 | $1.54M | +3.93% | ||
2024-09-09 | Sale | CFO AND TREASURER | 4,536 0.0101% | $345.41 | $1.57M | +2.73% | ||
2024-09-04 | Sale | director | 4,300 0.0097% | $353.36 | $1.52M | +1.16% | ||
2024-09-03 | Sale | CFO AND TREASURER | 4,519 0.0104% | $362.37 | $1.64M | +1.33% |
PATUSKY CHRISTOPHER | director | 900 0.002% | $366.99 | 5 | 68 | <0.0001% |
ROTHBLATT MARTINE A | Chairperson & CEO | 130 0.0003% | $366.99 | 30 | 1099 | +20.16% |
BlackRock | $1.28B | 12.55 | 5.57M | +5.15% | +$62.61M | 0.03 | |
The Vanguard Group | $1.08B | 10.56 | 4.68M | +0.2% | +$2.16M | 0.02 | |
Wellington Management Company | $783.86M | 7.69 | 3.41M | -10.06% | -$87.7M | 0.13 | |
Avoro Capital Advisors Llc | $656.74M | 6.45 | 2.86M | 0% | +$0 | 7.87 | |
Renaissance Technologies | $494.29M | 4.85 | 2.15M | -0.85% | -$4.25M | 0.79 |